Sibel Dogan-Gunaydin

11PUBLICATIONS
20CO-AUTHORS
Predictive and prognostic markersNutritional epidemiologyPharmacogenomicsAllergyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Jun 27, 2025
Early response is a strong predictor of the long-term response in psoriasis patients receiving risankizumab or guselkumab in the real-world: a retrospective analysis.

Neslihan Akdogan, Ömer Kutay Mutlu, Erdem Karabulut

|Jan 08, 2025
The Impact of Diet on Hidradenitis Suppurativa Severity: A Cross-Sectional Case-Control Study.

Ferhan Kesik, Sibel Dogan-Gunaydin, Mehmet Fisunoglu

|Jul 12, 2024
Psoriatic arthritis, biologic therapy experience, body mass index, and onset age of psoriasis were independent factors of secukinumab discontinuation in patients with psoriasis.

Neslihan Akdogan, Kerem Balan, Basak Yalici Armagan

|Jun 07, 2024
Identifying epidermolysis bullosa subtypes through immune antigenic mapping in Turkish patients.

Sibel Doğan Günaydın, Özay Gököz, Başak Yalıcı Armağan

|Dec 06, 2021
Sarcoid-like granulomatous reaction in the lung mimicking miliary tuberculosis in a patient receiving adalimumab for psoriasis.

Neslihan Akdoğan, Sibel Doğan, Rıdvan Bayler

|Oct 05, 2021
Comparison of rituximab and intravenous immunoglobulin in the treatment of autoimmune bullous diseases: Real-life data from a single centre.

Leyla Huseynova Terzi, Neslihan Akdogan, Sibel Dogan Gunaydin

Pageof 2

Frequent Collaborators

8 joint publications

Neslihan Akdogan

5 joint publications

Başak Yalıcı Armağan

3 joint publications

Nilgun Atakan

2 joint publications

Ecem Bostan